Noninvasive Characterization of the Histopathologic Features of Pulmonary Nodules of the Lung Adenocarcinoma Spectrum using Computer-Aided Nodule Assessment.

Slides:

Advertisements

Similar presentations

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

Advertisements

Computer-Aided Nodule Assessment and Risk Yield Risk Management of Adenocarcinoma: The Future of Imaging? Finbar Foley, MD, MPH, Srinivasan Rajagopalan,

Radiation Therapy for Invasive Breast Cancer Increases the Risk of Second Primary Lung Cancer: A Nationwide Population-Based Cohort Analysis Yi-Jhih.

FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies Marcelo F.K. Benveniste, MD, Cesar A.

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC Thibaud P. Coroller, MSc, Vishesh Agrawal, MD, Elizabeth.

Preoperative Localization of Lung Nodules With Fiducial Markers: Feasibility and Technical Considerations Amita Sharma, MD, Shaunagh McDermott, MD, Douglas.

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

The Lung Reporting and Data System (LU-RADS): A Proposal for Computed Tomography Screening Daria Manos, MD, Jean M. Seely, MD, Jana Taylor, MD, Joy Borgaonkar,

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

ALK FISH and IHC: You Cannot Have One without the Other

Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P

Mark F. Berry, MD, Thomas A. Sporn, MD, Joseph O. Moore, MD, Thomas A

Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

Ashok K. Malani, MD, MS, Brian Olofsson, MD, David Debono, MD

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience Ramsey Asmar, MD, Joshua R. Sonett, MD,

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Imaging Phenotyping Using Radiomics to Predict Micropapillary Pattern within Lung Adenocarcinoma So Hee Song, MD, Hyunjin Park, PhD, Geewon Lee, MD,

Frank Detterbeck, MD Journal of Thoracic Oncology

Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Generation and Sequencing of Pulmonary Carcinoid Tumor Cell Lines

Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis Xin Luo, MD, Xiao Zang, BS, Lin Yang, MD, Junzhou Huang, PhD,

Nomogram for Predicting the Risk of Invasive Pulmonary Adenocarcinoma for Pure Ground-Glass Nodules Lijie Wang, MD, Weiyu Shen, MD, Yong Xi, MD, Shuai.

How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed? Yoshihisa Kobayashi, MD, Takayuki Fukui, MD, Simon Ito, MD, Noriyasu Usami, MD,

Patients’ Knowledge, Beliefs, and Distress Associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter.

A Two-Faced Young Woman

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer Pierre.

Noninvasive Risk Stratification of Lung Adenocarcinoma using Quantitative Computed Tomography Sushravya Raghunath, PhD, Fabien Maldonado, MD, Srinivasan.

Ping Yang, MD, PhD, Kimary Kulig, PhD, MPH, Jennifer M

High-resolution computed tomography with three-dimensional reconstruction for assessment of chronic pulmonary thromboembolic disease Thoralf M. Sundt,

Validation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma Raphael Bueno, MD, Elisha.

New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation Between Multiple Lung Nodules with Ground-Glass Opacity Differentiates.

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Pneumatosis Cystoides Intestinalis After Gefitinib Therapy for Pulmonary Adenocarcinoma Masahiro Iwasaku, MD, Hiroshige Yoshioka, MD, Yohei Korogi, MD,

Laurie A. Hohberger, MD, Darrell R. Schroeder, MS, Brian J

Observer Variability in Mesothelioma Tumor Thickness Measurements: Defining Minimally Measurable Lesions Samuel G. Armato, PhD, Anna K. Nowak, MD, PhD,

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

Nasion Swelling as the Presenting Symptom of Lung Adenocarcinoma

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Pulmonary Metastases from Cervical Adenocarcinoma Regress to a ‘Hole’ Lot of Nothing Michael Guandalini, MBBS (Hons), BPhty, Karin Steinke, MD, MS, PD,

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

S768I Mutation in EGFR in Patients with Lung Cancer

Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma Mitchell Machtay, MD, Rebecca Paulus, BS, Jennifer.

Matthew Reichert, MD, Eric S. Bensadoun, MD

Yusuke Takahashi, MD, PhD, Prasad S. Adusumilli, MD

Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns Kuo-Hsuan Hsu, MD, Kun-Chieh Chen, MD,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

M. Kusumoto Journal of Thoracic Oncology

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed.

Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section.

Transcutaneous Computed Bioconductance Measurement in Lung Cancer: A Treatment Enabling Technology Useful for Adjunctive Risk Stratification in the Evaluation.

Linda L. Garland, MD, Kari Chansky, MS, Antoinette J

European Lung Cancer Conference (ELCC) 2016 Organisation

Recurrent Primary Synovial Sarcoma of the Chest Wall

Follow-Up of Small (4 mm or Less) Incidentally Detected Nodules by Computed Tomography in Oncology Patients: A Retrospective Review Reginald F. Munden,

Cristiano Rampinelli, MD, Vittoria Vecchi, MD, Massimo Bellomi, MD

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Presentation transcript:

Noninvasive Characterization of the Histopathologic Features of Pulmonary Nodules of the Lung Adenocarcinoma Spectrum using Computer-Aided Nodule Assessment and Risk Yield (CANARY)—A Pilot Study Fabien Maldonado, MD, Jennifer M. Boland, MD, Sushravya Raghunath, MS, Marie Christine Aubry, MD, Brian J. Bartholmai, MD, Mariza deAndrade, PhD, Thomas E. Hartman, MD, Ronald A. Karwoski, BS, Srinivasan Rajagopalan, PhD, Anne-Marie Sykes, MD, Ping Yang, MD, PhD, Eunhee S. Yi, MD, Richard A. Robb, PhD, Tobias Peikert, MD Journal of Thoracic Oncology Volume 8, Issue 4, Pages 452-460 (April 2013) DOI: 10.1097/JTO.0b013e3182843721 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 CANARY workflow outlining the procedural steps involved in categorizing the HRCT-based nodules into one of AIS, MIA, and IA. The first step involves the automated lung parenchymal isolation and classification using CALIPER. Subsequently, each nodule is identified by the operator using seed placement. This is followed by the automated volumetric extraction of the nodule and the characterization of each voxel within a given nodule based on the nine exemplars. This distribution of the exemplars within an individual lesion is then used to categorize each nodule. AIS, adenocarcinoma in situ; CALIPER, computer-aided lung informatics for pathology evaluation and rating; CANARY, computer-aided nodule assessment and risk yield; HRCT, high-resolution computed tomography; IA, invasive adenocarcinoma; MIA, minimally invasive adenocarcinoma. Journal of Thoracic Oncology 2013 8, 452-460DOI: (10.1097/JTO.0b013e3182843721) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Natural clustering of HRCT regions of interest (ROI) of lung nodules. (A) Representative ROIs selected from different nodules in the training set. Each of the 774 ROI was compared with each other to derive the pairwise 774 × 774 similarity matrix and color coded (B) such that the darkness is proportional to the similarity. (C) Similarity matrix in the affinity propagation–based clustered space wherein the arbitrarily color-coded diagonal sub-blocks show the automatically computed natural clusters. HRCT, high-resolution computed tomography. Journal of Thoracic Oncology 2013 8, 452-460DOI: (10.1097/JTO.0b013e3182843721) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Representative signatures for invasive adenocarcinoma (IA), minimally invasive adenocarcinoma (MIA), and adenocarcinoma in situ (AIS) (A). Representative CT images with the superimposed distribution of the nine adenocarcinoma exemplars are shown for IA, MIA, and AIS. (B) Three-dimensional distribution of the nine adenocarcinoma exemplars using multidimensional scaling. It demonstrates the secondary clustering of the exemplars; violet–indigo–red–orange (V-I-R-O) representing invasion, yellow–pink (Y-P) and blue–green–cyan (B-G-C) representing lepidic growth. CT, computed tomography. Journal of Thoracic Oncology 2013 8, 452-460DOI: (10.1097/JTO.0b013e3182843721) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Radiologic–histopathologic correlation of tissue invasion between CANARY-based nodule assessment and consensus histopathology. Examples of representative CT images with superimposed CANARY “signatures” (distinctive combinations of exemplars within one nodule) associated with nodules with varying degrees of histologic invasion (%, 100—consensus histopathology lepidic growth %) (A). Correlation between CANARY and consensus histopathology for pulmonary nodules of the adenocarcinoma spectrum, training set, excluding 16 cases used to develop CANARY (n = 38) (B) and validation set (n = 86) (C). Spearman correlation (p < 0.0001), line represents linear regression (B and C). CANARY, computer-aided nodule assessment and risk yield; CT, computed tomography. Journal of Thoracic Oncology 2013 8, 452-460DOI: (10.1097/JTO.0b013e3182843721) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Rule-based CANARY decision algorithm based on the distribution of exemplar clusters (%): violet–red–orange (VIRO), yellow–pink (YP), and blue–green–cyan (BGC) within each lesion. CANARY, computer-aided nodule assessment and risk yield. Journal of Thoracic Oncology 2013 8, 452-460DOI: (10.1097/JTO.0b013e3182843721) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Two by two contingency table of CANARY's diagnostic performance (rows) to predict consensus histopathologic tissue invasion (columns). (A) Training set (n = 54). (B) Validation set (n = 86). CANARY, computer-aided nodule assessment and risk yield. Journal of Thoracic Oncology 2013 8, 452-460DOI: (10.1097/JTO.0b013e3182843721) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Lung cancer–specific postoperative survival. (A) Consensus histopathology and (B) CANARY. CANARY, computer-aided nodule assessment and risk yield. Journal of Thoracic Oncology 2013 8, 452-460DOI: (10.1097/JTO.0b013e3182843721) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 8 Representative nodules with discrepant radiologic and histologic classification. Nodules in (A) and (B) were categorized differently by the expert radiologists (IA versus MIA) but correctly identified by CANARY (histologic consensus MIA). Histology confirmed MIA nodules in (C) and (D) were categorized by both radiologists as IA. The histologically confirmed IA nodule in (E) was categorized by both the radiologists as MIA. The rule-based CANARY categorization of these nodules was the same as histology consensus. CANARY, computer-aided nodule assessment and risk yield; IA, invasive adenocarcinoma; MIA, minimally invasive adenocarcinoma. Journal of Thoracic Oncology 2013 8, 452-460DOI: (10.1097/JTO.0b013e3182843721) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions